EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Mogamulizumab efficacy on the skin compartment of cutaneous T‐cell lymphomas based on longitudinal analysis

Nobuaki Nakano iD, Kenta Murotani iD, Yoshito Ohya iD, Yukihiro Nishio iD

British Journal of Haematology · 21.10.2026

DOI: 10.1111/bjh.70879 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 21.10.2026. Verfasst von Nobuaki Nakano und 3 weiteren Autor:innen. Beteiligte Einrichtung: Seifukai Clinic, Miyakonojo, Japan. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Kyowa Kirin Co. Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cutaneous T‐cell lymphoma is staged by the degree of skin, lymph node, viscera and blood involvement. Skin response is a determinant of treatment decisions. Mogamulizumab, an anti‐CC chemokine receptor 4 antibody, is approved for mycosis fungoides and Sézary syndrome after ≥1 systemic therapy. Longitudinal changes in modified Severity‐Weighted Assessment Tool (mSWAT) score, and cluster of differentiation (CD)4 + CD7 − /CD26 − cell subsets during mogamulizumab treatment were investigated as an exploratory post‐hoc analysis. While chronological differences in mSWAT scores were not interpreted by a linear mixed model (LMM) due to a statistically significant interaction term, significant differences based on responses in CD7 − (−690.5/μL; 95% confidence interval [CI], −1195 to −186.2; p = 0.0076) and CD26 − (−1029/μL; 95% CI, −1705 to −353.7; p = 0.0030) cell counts were identified. Actual values of mSWAT scores decreased for responders at Week (W) 12 and 24 from baseline (BL) (mean ± standard error: BL: 97.57 ± 6.52; W12: 52.34 ± 6.16; W24: 34.89 ± 4.93) following a rapid decrease of CD7 − cells in blood at W4 (BL: 2809 ± 650.3/μL; W4: 204.4 ± 50.76/μL; W12: 101.9 ± 28.81/μL; W24: 152.8 ± 54.98/μL). Monitoring both blood and skin improvements is important for effective mogamulizumab treatment in patients with advanced stage disease.

Schlagwörter

Stichwörter der Autor:innen

cutaneous T‐cell lymphomamSWATmogamulizumab

Autor:innen und Institutionen

  • Seifukai Clinic, Miyakonojo, Japan.
  • Biostatistics Center, Kurume University, Kurume, Japan.
  • Kyowa Kirin Co., Ltd, Tokyo, Japan.

ORCID-Profile: Nobuaki Nakano, Kenta Murotani, Yoshito Ohya, Yukihiro Nishio

Förderung

  • Kyowa Kirin Co. Ltd

Zitieren

APA

Nakano, N., Murotani, K., Ohya, Y., & Nishio, Y. (2026). Mogamulizumab efficacy on the skin compartment of cutaneous T‐cell lymphomas based on longitudinal analysis. British Journal of Haematology. https://doi.org/10.1111/bjh.70879

Vancouver

Nakano N, Murotani K, Ohya Y, Nishio Y. Mogamulizumab efficacy on the skin compartment of cutaneous T‐cell lymphomas based on longitudinal analysis. British Journal of Haematology. 2026. doi:10.1111/bjh.70879

BibTeX
@article{Nakano2026,
  author = {Nakano, Nobuaki and Murotani, Kenta and Ohya, Yoshito and Nishio, Yukihiro},
  title = {Mogamulizumab efficacy on the skin compartment of cutaneous T‐cell lymphomas based on longitudinal analysis},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70879}
}
Kostenlos starten →